Exelixis director sells 7,712 shares after option exercise

EXELIXIS, INC. director Mary C. Beckerle reported an exercise-and-sell transaction in company stock.

Rhea-AI Filing Summary

EXELIXIS, INC. director Mary C. Beckerle reported an exercise-and-sell transaction in company stock. She sold 7,712 shares of common stock in an open-market sale at $48.45 per share. She also exercised options to acquire 3,856 shares at an exercise price of $23.24 per share. Following these transactions, she holds 25,236 shares of common stock, including 17,524 shares that will be issued upon vesting of restricted stock units.

Insights

Equity compensation and insider-transactions analyst

Director executes routine option exercise and partial share sale with modest scale.

Director Mary C. Beckerle combined an option exercise with an open-market sale. She exercised options for 3,856 shares at $23.24 and sold 7,712 shares at $48.45. This pattern is common when insiders convert stock-based awards and monetize a portion.

After the transactions she still holds 25,236 shares, including 17,524 shares tied to RSUs that vest over time. The filing does not reference any trading plan or unusual conditions, so the activity appears routine and limited in size relative to her remaining stake.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 3 txns

Insider Beckerle Mary C

Role Director

Sold 7,712 shs ($374K)

Approx. gross sale proceeds $374K

Approx. exercise cost $90K

Type	Security	Shares	Price	Value
Exercise	Option (right to buy)	3,856	$0.00	$0.00
Exercise	Common Stock	3,856	$23.24	$90K
Sale	Common Stock	7,712	$48.45	$374K

Holdings After Transaction: Option (right to buy) — 12,854 contracts (Direct); Common Stock — 17,524 shares (Direct)

Footnotes (2)

1. F1. Includes 17,524 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock.
2. F2. The option, representing the right to purchase a total of 30,848 shares of Common Stock, became fully exercisable on January 5, 2024.

Key Figures

Shares sold: 7,712 shares Sale price: $48.45 per share Options exercised: 3,856 shares +4 more

7 metrics

Shares sold 7,712 shares Open-market sale of common stock

Sale price $48.45 per share Price received for common stock sale

Options exercised 3,856 shares Shares acquired via option exercise

Option exercise price $23.24 per share Exercise price for options converted to stock

Post-transaction holdings 25,236 shares Common stock held after transactions

RSU-related shares 17,524 shares Shares to be issued upon RSU vesting

Option grant size 30,848 shares Total shares underlying the option grant, fully exercisable

Key Terms

restricted stock units ("RSUs"), Option (right to buy), derivative security

3 terms

restricted stock units ("RSUs") financial

"Includes 17,524 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs")."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Option (right to buy) financial

"security_title": "Option (right to buy)""

derivative security financial

"transaction_code_description": "Exercise or conversion of derivative security""

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did EXEL director Mary C. Beckerle report?

Mary C. Beckerle reported selling 7,712 shares of EXELIXIS common stock. The shares were sold in an open-market transaction at $48.45 per share, alongside an option exercise, as disclosed in the Form 4 insider trading report.

At what prices did Mary C. Beckerle sell and acquire EXEL (EXEL) shares?

She sold common shares at $48.45 each and acquired shares by exercising options at $23.24 per share. This reflects converting previously granted options into stock, then selling a portion at the current market price.

How many EXELIXIS (EXEL) shares does Mary C. Beckerle hold after this Form 4?

After these transactions, she holds 25,236 shares of EXELIXIS common stock. That total includes 17,524 shares that will be issued in the future upon vesting of restricted stock units granted as equity compensation.

Did Mary C. Beckerle exercise stock options in this EXEL Form 4 filing?

Yes. She exercised options covering 3,856 shares of EXELIXIS common stock. The options had a $23.24 exercise price per share, converting them into common stock as part of a typical equity compensation realization event for a director.

What does the Form 4 say about Mary C. Beckerle’s EXEL restricted stock units (RSUs)?

The filing notes that 17,524 shares are tied to restricted stock units that will vest over time. Each RSU represents the economic equivalent of one EXELIXIS common share, which will be issued to her upon vesting, increasing her delivered share holdings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/08/2026 - 07:03 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Beckerle Mary C

(Last) (First) (Middle)

C/O EXELIXIS, INC.

1851 HARBOR BAY PARKWAY

(Street)

ALAMEDA CALIFORNIA 94502

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
EXELIXIS, INC. [ EXEL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/07/2026		M		3,856	A	$23.24	25,236(1)	D
Common Stock	05/07/2026		S		7,712	D	$48.45	17,524(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (right to buy)	$23.24	05/07/2026		M			3,856	01/05/2024(2)	01/04/2031	Common Stock	3,856	$0	12,854	D

Explanation of Responses:

1. Includes 17,524 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock.

2. The option, representing the right to purchase a total of 30,848 shares of Common Stock, became fully exercisable on January 5, 2024.

Remarks:

	/s/ Nina Ayer, Attorney in Fact	05/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)